Comparative Pharmacology
Head-to-head clinical analysis: ANHYDRON versus CHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANHYDRON versus CHLOROTHIAZIDE.
ANHYDRON vs CHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
500 mg to 1000 mg orally or intravenously once or twice daily.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateChlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateTerminal half-life: 45–120 minutes (prolonged in renal impairment); clinical context: short duration requires frequent dosing
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Renal: ~95% (tubular secretion); Fecal: <5%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Chlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin."